Correction

A Pipeline Plus article in the January 2016 issue of P&T (“Multiple Myeloma Market Will Expand With Launch of Monoclonal Antibodies,” page 64) incorrectly stated that daratuzumab (Darzalex, Genmab/Janssen) is coadministered with bortezomib (Velcade, Takeda Oncology) and dexamethasone (Table 1). Daratuzumab was approved by the Food and Drug Administration as monotherapy for patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent. The recommended dosage is 16 mg/kg weekly from weeks 1 to 8; then every two weeks from weeks 9 to 24; and then every four weeks from week 25 onwards until disease progression.